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Abstract  
BACKGROUND: A noninvasive, highly sensitive and specific urine test is needed for bladder 
cancer (BC) diagnosis and surveillance  in addition to the invasive cystoscopy. We previously 
described the diagnostic effectiveness of urinary tyrosine-phosphorylated proteins (UPY) and a new 
assay (UPY-A) for their measurement in a pilot study. The aim of this work was to evaluate the 
performances of the UPY-A using an independent cohort of 262 subjects.  
METHODS: UPY were measured by UPY-A test. The area under ROC curve, cut-off, sensitivity, 
specificity and predictive values of UPY-A were determined. The association of UPY levels with 
tumor staging, grading, recurrence and progression risk was analyzed by Kruskal-Wallis and 
Wilcoxon test. To test the probability to be a case if positive at the UPY-A, a logistic test adjusted 
for possible confounding factor was used. 
RESULTS: Results showed a significant difference of UPY levels between patients with BC vs 
healthy controls. For the best cut-off value, 261.26 Standard Units (SU), the sensitivity of the assay 
was 80.43%, and the specificity 78.82. A statistically significant difference was found in the levels 
of UPY at different BC stages and grades between Ta and T1 and with different risk of recurrence 
and progression. A statistically significant increased risk for BC at UPY-A ≥ 261.26 SU was 
observed.  
CONCLUSIONS: The present study supplies important information on the diagnostic 
characteristics of UPY-A revealing remarkable performances for early stages and allowing its 
potential use for different applications encompassing the screening of high-risk subjects, primary 
diagnosis and post-treatment surveillance. 
 
Keywords: Bladder cancer; Urinary tyrosine-phosphorylated proteins; Urinary tumor markers; 
Diagnostic assay. 
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Urinary bladder cancer (BC) ranks 9th in cancer incidence worldwide (Ploeg et al, 2009;  Chavan et 
al, 2014). The diagnosis is made after symptom observation and urethro-cystoscopy (UCS) (Boman 
et al, 2002; Babjuk et al, 2013). More than 50% of non-muscle-invasive (NMIBC: CIS, Ta, T1) 
patients will experience at least one recurrence while 10 to 15% will have a progression to an 
invasive form (Simon et al, 2003). Patients undergo a lifelong follow-up, and also for this reason 
BC is the most costly cancer from diagnosis to death (Gore and Gilbert, 2013; Hong and Loughlin, 
2008). 
Several markers have been proposed, but none of them was able to replace the UCS in the diagnosis 
and follow-up of BC (Cheung et al, 2013) as documented by the current urological guidelines 
(AUA, EAU, NCCN). It should be noticed that estimates of UCS false-negative range from 10% to 
40% (Kriegmair et al, 1996; Zaak et al, 2001; Schneeweiss et al, 1999), and specificity can be as 
low as 37% (Sarosdy et al, 2002). Although available urine markers are not usually considered to 
possess sufficient sensitivity and specificity for the screening of BC in the general population 
(Cheung et al, 2013; Parker and Spiess, 2011), many markers have shown potential value in 
improving diagnostic accuracy when used to complement current strategies or when multiple 
markers are used (Miremami et al. 2014). Nevertheless, it should be noticed that some markers with 
comparable performances are used for the screening of other tumors (Greene et al, 2009). As a 
possible cause of their limited use, the urinary tests showing better diagnostic performances as 
uCyt+/immunoCyt, microsatellite and FISH require personnel with specific training, have low 
throughput and are very expensive (Cheung et al, 2013). Therefore, to be widely usable and to 
allow a wide clinical validation, new urinary tests for BC should be standardized, easier to interpret 
and cost-effective (Cheung et al, 2013).  
The present study grounds on our previous proteomic analyses of BC tissue and urine revealing the 
presence of anomalous levels of tyrosine-phosphorylated proteins (UPY) (Khadjavi et al, 2011). 
UPY showed remarkable stability in urine but their low concentration initially required complex 
and expensive proteomic techniques for their measurement (Khadjavi et al, 2011), thus limiting 
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their practical utility. Substantial work was then required to miniaturize the method encompassing 
all purification and detection steps, to standardize the results and to limit the assay costs. Its 
performances were investigated in a training set of subjects (Khadjavi et al, 2013). Therefore the 
aim of the present study was to  evaluate the UPY assay (UPY-A) in an independent set of subjects 
and its diagnostic performances at different tumor stages and grades, its association with tumor 
progression and recurrence risk and the effects of possible confounding factors such as age, 
smoking status and gender.  
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Materials and Methods 
Patients and sample collection  
Urine samples from newly diagnosed BC patients were collected at the Department of Urology of 
our Institution. Urine samples from healthy volunteers were obtained from the Blood Bank of the 
same hospital. Patients with suspected BC were enrolled in this study before undergoing 
transurethral resection (TUR) of the bladder. Patients with a histological diagnosis (reference 
standard) different from BC or with a previous BC history were subsequently excluded. The list of 
recruited patients included people who: 1) received a first diagnosis of BC between September 2010 
to May 2012; 2) lived in the study area at the time of diagnosis; 3) were over age 18 years; 4) were 
able to provide interview data. Healthy controls included people that did not present symptoms or 
signs of BC, previous BC history and meeting the criteria 2, 3 e 4. All recruited subjects underwent 
the test. The study was approved by the local research Ethical Committee and was conducted 
according to Helsinki Declaration's prescriptions. All the subjects included in the protocol signed a 
declaration of informed consent and received a brief questionnaire covering detailed medical and 
personal information. The subjects were classified as “current smokers”, “former smokers” (quit 
smoking for at least ten years) and “nonsmokers”. A total of 260 participants provided age 
information,  239 smoking status and 262 gender information. BC grade and stage were determined 
according to WHO (1973 and 2004) criteria and TNM classification, respectively. Risk scores for 
recurrence and progression were calculated for each patient affected by NMIBC according to the 
EORTC definition. These factors comprise tumor grade, stage, size, number and concomitant CIS. 
Based on these scores, patients were considered to have Very low (score 0), Low (score 1-4), 
Moderate (score 5-9), or High (score 10-17)risk for recurrence and Very low (score 0), Low (score 
2-6), Moderate (score 7-13), or High (score 14-23) risk for progression (Babjuc et al, 2014). Voided 
urine samples (10-50 ml) were collected from the second micturition of the morning. Samples were 
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stored at -20°C within 2 hours from collection. The test was performed within 6 months from 
collection. No significant decay of UPY levels have been noticed after two years of cold storage. 
Measurement of urine tyrosine-phosphorylated proteins  
Urine samples were centrifuged for 20 minutes at 700 x g at 10°C and supernatants were collected. 
Five hundred μl of supernatant from each patient were processed using the UPY-A (Khadjavi et al, 
2013). Detection was performed by employing a standard chemiluminescence reader (Synergy HT 
Multi-Mode Microplate Reader, Biotek): luminescence end-point, sensitivity 100 and integration 
time 1.0 ss. Using an external peptide calibration curve, UPY levels were interpolated and 
expressed as Standard Units (SU).   
Statistical analyses 
Summary data are presented as means, medians and standard deviations for continuous variables 
and as percentages for categorical variables. Differences between BC cases and healthy controls 
were tested using the nonparametric Wilcoxon rank sum test or Chi-square test, for continuous 
variables or categorical variables, respectively. The accuracy of the UPY-A biomarker was tested 
computing the area under the ROC curve (AUC). Different cut-off levels were used to determine 
that which performs better. Positive predictive value (PPV) and negative predictive value (NPV) 
were also computed at each cut-off point. The Kruskal-Wallis test was used to assess if UPY levels 
were different between groups characterized by different tumor stage and grade as well as different 
recurrence or progression risks. The increase in the prediction performance in predicting recurrence 
and progression given by the UPY-A marker with respect to the EORTC risk class, was evaluated 
computing the AUC of three logistic models including age, gender, smoke:  model 1: + EORTC risk 
class; model 2: + UPY-A marker; model 3: + UPY-A marker + EORTC risk class. The AUC of the 
three models were compared by means of the DeLong test (DeLong et al, 1988). To test the 
probability to be a case if positive at the UPY-A, we used a multivariate logistic regression adjusted 
for age, smoking status and gender. All tests were two-sided  and we considered a 5% significance 
level. Analyses were performed using SAS V9.2. 
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Results 
Evaluation and optimization of urine tyrosine-phosphorylated protein assay  
To evaluate the results concerning UPY obtained in the pilot study (Khadjavi et al, 2013) in an 
independent cohort of subjects, 262 new urinary samples collected from 92 BC patients and 170 
healthy subjects were analyzed (Table 1). UPY levels showed a significant difference (p=1.71x10-23 
Wilcoxon rank sum test) between patients with BC vs healthy controls (means: 434.8±258.4 SU vs 
157.9±114.6 SU), corresponding to an approximately 4-fold increase of UPY (Figure 1A). We 
performed ROC curve analysis (Figure 1B) and the ROC AUC including UPY-A, age, smoking 
status and gender as predictors was 0.92 with a 95% confidence interval of 0.89-0.97. For the best 
cut-off value (261.26 SU), the performances of the UPY-A, using only the test as a predictor, were 
calculated, displaying a sensitivity of 80.43% and a specificity of 78.82% with a PPV of 67.3% and 
a NPV of 88.2%. It should be noticed that the sensitivity of the assay is still 57.61% with 95.29% of 
specificity. In order to evaluate possible interferences, we tested 16 urine samples from patients 
with cystitis and variable levels of leukocyturia and hematuria. The obtained results (mean values: 
179.1 ± 117.1 SU) were not significantly different from control subjects (p=0.364 Wilcoxon rank 
sum test).  
Diagnostic performances of urine tyrosine-phosphorylated protein assay at different stages 
and grades of bladder cancer 
The diagnostic performances of the assay have been evaluated according to tumor stages and 
grades. Figure 2A shows the levels of UPY-A in control, CIS, Ta, T1, T2-3 tumor stages, while 
panel B shows the variations observed in G1, G2 and G3. A statistically significant difference was 
found in UPY levels between the control group and the groups of patients at different tumor stages 
and grades (p=8.10x10-22 and p=6.99x10-22 respectively by Kruskal-Wallis test). Table 2 shows the 
p-values for the pairwise Wilcoxon rank sum test, evaluating different levels of UPY among 
different stages (A), and grades (B) and the P values (on the bottom) for the overall Kruskall-Wallis 
8 
 
test, taking controls samples as reference. In particular, a statistically significant difference was 
observed through UPY-A at early stages between Ta and T1 (p=0.008 by Wilcoxon rank sum test) 
(see also Figure 2A and Figure 2B).  The sensitivity and specificity of the assay at various stages 
and grades are displayed in Table 3, with the specificity being fixed at 78.82% to facilitate the 
comparison of the sensitivities. Consistently with the results shown in Figure 2A, the sensitivity of 
the assay displayed striking increases from Ta to T1 or T2-3 (from 69.81% to 95.00% or 93.33%)  
and a less pronounced increase from G1 to G2 (from 68.97% to 79.31%). A remarkable increase of 
sensitivity was also observed from G2 to G3 (from 79.31% to 90.00%). With fixed specificity at 
90% (cut-off value: 335.57 SU), the sensitivities were 50.94% for Ta, 80.00 % for T1 and T2-3. 
Increasing the cut-off value to 373.39 SU (thus leading specificity to 95.29%), a sensitivity decrease 
was observed especially for the earlier stages of BC, yet the observed values were still above 
47.17% and 75.00 % in Ta and T1 respectively. We performed also the analysis of UPY levels in 
patients classified according to WHO 2004 classification of BC and we observed a statistically 
significant difference between the low grade and high grade patients as shown in Figure 3 
(p=0.0005 by Wilcoxon rank sum test). Moreover, a statistically significant difference was found in 
the levels of UPY in groups of patients with different risk of recurrence (p=0.002 by Kruskal-Wallis 
test) (Figure 4A) and progression (p=0.001 by Kruskal-Wallis test) (Figure 4B). In particular, UPY 
levels in Very low/Low recurrence risk groups were lower than those in Moderate risk group 
(p=0.004 and p=0.002 respectively by Wilcoxon rank sum test), whereas levels of UPY in Very low 
progression risk group were lower than those in moderate risk group (p=0.001 by Wilcoxon rank 
sum test) strengthening the biological plausibility of the association and indicating that UPY-A 
could help in the prediction of progression and recurrence of BC. The increase in the prediction of 
recurrence and progression given by the UPY-A marker was also evaluated. The AUC of the model 
including EORTC risk class as predictor (model 1) was 0.61 (0.45 – 0.76); the AUC of the model 
including UPY-A marker as predictor (model 2) was 0.69 (0.54 – 0.83); finally the AUC of the 
model including both variables (model 3) was 0.70 (0.56 – 0.84). The increase in prediction 
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performance was evaluated by the De Long test (model 2 vs. model 1 p = 0.30; model 3 vs. model 1 
p = 0.21). 
 
Effect of possible confounding factors on the diagnostic performances of UPY-A 
To assess the effect of possible confounding factors, we compared UPY levels in the healthy control 
group stratified for age, smoking status and gender (data are shown in Supplemental Figure S1). 
The differences in smoking status (p=0.51 by Kruskal-Wallis test) and gender (p=0.35 by Wilcoxon 
rank sum test) were not statistically significant. On the contrary, after comparing the group of 
healthy controls older than 55 years (mean 168.6±109.4 SU) to those younger than 55 years (mean 
134.3±123.0 SU), age-related differences were statistically significant (p=0.017 by Wilcoxon rank 
sum test), with lower UPY levels in the younger group. Odd ratios (ORs) and 95% confidence 
intervals (CIs) were calculated by logistic regression for potential confounders. A statistically 
significant increased risk for BC among subjects presenting the UPY-A ≥ 261.26 SU was observed 
(OR= 15.30, 95% CI = 8.12–28.82). OR was still significant after the adjustment for age, smoking 
status and gender. Since among healthy controls the subjects older than 55 years were significantly 
different for UPY-A compared to younger controls, healthy controls and BC patients were stratified 
in four additional different age groups. Figure 5A shows that UPY levels are significantly increased 
in BC patients vs healthy controls in all age groups. The figure also highlights that healthy controls 
under 55 years display lower UPY levels with respect to older controls, not showing reciprocal 
variations. On the other hand, BC patients showed a progressive increase of UPY with the age due 
to the increasing prevalence of more advanced tumor stages in older patients.  In patients under 55 
years we observed a large prevalence of Ta and G1 (Figure 5B and 5C). As a matter of facts the best 
cut-off limit in this age group was 180 SU instead of 261.26 SU. With this cut-off limit sensitivity 
improved from 54.5% to 81.8%.  
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Discussion 
Changes of protein tyrosine-phosphorylation are involved in cell growth and differentiation and 
have been observed in many cancer types, usually as a consequence of altered tyrosine kinase 
activity (Lim, 2005; Blume-Jensen and Hunter, 2001; Harsha and Pandey, 2010). On the other hand, 
tyrosine kinases are amongst the most important oncogenes known to date, since they play a central 
role in cancer development and progression (Lim, 2005; Blume-Jensen and Hunter, 2001; Hunter, 
1998). Robust evidence demonstrates the involvement of abnormal kinase activity in BC following 
mutations and/or overexpression of protein kinases (Al Hussain and Akhtar, 2013), protein hyper-
phosphorylation in biopsy specimens (Khadjavi et al, 2011) and after using tyrosine kinase 
inhibitors for BC treatment (Wallerand et al, 2010; Mitra et al, 2006). FISH analysis of Aurora 
kinase A has been used as a marker for BC (Park et al, 2008).  
Measuring the effects of abnormal protein kinase activity on protein phosphorylation takes 
advantage from a substantial amplification of the signal, as a consequence of increased catalytic 
activity of the mutated kinase. However, the instability of phospho-proteins in blood has limited 
their use for cancer diagnosis. On the contrary, we previously observed that protein phosphatases 
activity is negligible in urine, thus conferring a particular stability to urinary phospho-proteins 
(Khadjavi et al, 2011). Nevertheless, only a small amount of phospho-proteins is associated to BC, 
therefore stringent purification steps and high sensitivity detection methods are required (Khadjavi 
et al, 2011; Khadjavi et al, 2013).  
The present report evaluates and optimizes the performances of the UPY examined in the pilot 
study (Khadjavi et al, 2013) by confirming the high sensitivity and specificity of the assay to detect 
BC in an independent and larger cohort of subjects. A statistically significant difference was found 
in the levels of UPY at different BC stages and grades. Sensitivity values have been measured at 
different fixed specificities. As shown in Table 3 UPY-A with chosen specificity comparable to 
cytology (> 93%) displays higher sensitivity in Ta (47% vs 26%) and T1 (74% vs 64%) respectively 
and more than 2-fold higher sensitivity in G1 subjects (41% vs 6%) (for the cytology data see Saad 
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et al. 2001). Nevertheless, the comparison with other techniques is very complex, and larger and 
independent studies are certainly needed. The comparison should also consider additional 
characteristics such as the cost, the productivity and the intra/inter-laboratory standardization of  the 
test. At this regard, UPY-A will be in the cost range of an ELISA test such as BTA and NMP22 tests 
with additional advantages as UPY-A high throughput and the possibility of automated calibration 
in each analytical sessions, making it simpler to standardize than techniques requiring larger effort 
for inter-laboratory harmonization (Behrens et al, 2014).  
In the present report we have also observed that UPY-A can identify patients more prone to 
recurrence and progression. Therefore, these patients could receive closer surveillance or more 
aggressive therapy. Of note, the increase in the prediction performance in predicting recurrence and 
progression given by the UPY-A with respect to the EORTC risk class, is not statistically significant 
but the association of the UPY-A and the EORTC classification improves the recurrence and 
progression prediction. We also have excluded that age, smoking status and gender can affect the 
diagnostic performances of the assay as confounding factors. Nevertheless, taking in account that 
the average values of the test were lower in younger healthy subjects (≤ 55 years old), we have 
found that lowering the cut-off limit in this group of subjects determined a significant improvement 
of sensitivity. Therefore, these results encourage further studies involving a wider number of 
patients younger than 55 year, in order to optimize the cut-off values. Interestingly, a first 
preliminary investigation on a group of patients with nonmalignant urological disorders did not 
reveal considerable interference. Large and independent studies are currently in progress to confirm 
the present data and to evaluate the value of UPY-A in the follow-up of BC patients. 
In conclusion, the present study supplies important information on the diagnostic characteristics of 
UPY-A revealing remarkable performances for early stages. The efforts made to miniaturize the 
method markedly increased its throughput allowing its potential use for a wide range of applications 
encompassing the screening of high-risk subjects, primary diagnosis and post-treatment 
surveillance.  
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Table 1. Clinical and pathologic characteristics of subjects 
 Controls Bladder Cancer Cases
 N° % N° %
Total (n=262) 170 65 92 35
Sex  
Women 39 15 6 2
Man 131 50 86 33
Age  
≤55 53 20 11 4
56-65 72 28 25 9
66-75 28 11 37 14
>75 15 6 19 7
Missing 2 1   
Smoking  
Current smokers 28 11 53 20
Former smokers 10 4 20 8
Non smokers 111 42 17 6
Missing 21 8 2 1
Histology at 1st diagnosis  
CIS   4 4
Ta   53 53
T1   20 22
T2-3   15 16
Grading at 1st diagnosis  
CIS   4 4
1   29 33
2   29 33
3   30 34
WHO 2004  
Low grade   43 47
High grade   43 47
Missing   6 6
Risk of recurrence  (n=73) 
Very low   24 33
Low   40 55
Moderate   9 12
Risk of progression (n=73) 
Very low   40 55
Low   17 23
Moderate   16 22
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Table 2. p-values for the pairwise Wilcoxon rank sum test, evaluating different levels of 
urinary tyrosine-phosphorylated protein (UPY) among different stages (A) and grades (B). p- 
values on the bottom refers to the overall Kruskall-Wallis test. Controls samples were taken as 
a reference 
 
 
 
 A CTRL CIS Ta T1 T2-3 B CTRL G1 G2 G3
CTRL - 0.004 4.26x10-13 3.11x10-11 1.55x10-7 CTRL - 3.04x10-7 7.02x10-11 2.83x10-14
CIS - - 0.532 0.439 0.230 G1 - - 0.592 0.002
Ta - - - 0.009 0.005 G2 - - - 0.001
T1 - - - - 0.368 G3 - - - -
T2-3 - - - - - - - - - -
p= 8.10x10-22 p = 6.99x10-22 
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Table 3. Diagnostic performances of urinary tyrosine-phosphorylated protein assay (UPY-A) 
at different BC stages and grades 
BC stage or 
grade 
AUC 
(area under 
ROC curve) 
95% 
confidence 
interval 
sensitivity  
(specificity 78.82 %)  
(cut-off value 261.26 SU) 
sensitivity  
(specificity 90.00 %) 
(cut-off value 335.57 SU) 
sensitivity  
(specificity 95.29 %) 
(cut-off value 373.39 SU) 
CIS 0.924 0.873-0.958 100% 50.00% 50.00% 
Ta 0.830 0.774-0.877 69.81% 50.94% 47.17% 
T1 0.954 0.914-0.979 95.00% 80.00% 75.00% 
T2-3 0.909 0.858-0.946 93.33% 80.00% 73.33% 
G1 0.798 0.735-0.851 68.97% 48.28% 41.38% 
G2 0.879 0.826-0.921 79.31% 51.72% 48.28% 
G3 0.936 0.892-0.966 90.00% 86.67% 83.33% 
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Titles and legends to figures 
Figure 1. Urinary tyrosine-phosphorylated protein (UPY) levels in urine samples. (A) Analysis 
of urinary UPY levels in samples of healthy subjects (n= 170) and bladder cancer (BC) patients (n= 
92) using the UPY-A. Healthy subject (CTRL) mean levels: 157.9±114.5 SU; BC mean levels: 
434.8±258.4 SU. Significance of the differences: p=1.71x10-23 by Wilcoxon rank sum test . The 
solid lines indicate the mean values; the dotted line indicates the best cut-off value. (B) ROC curve 
of total UPY levels adjusted for age, smoking status and gender. 
Figure 2. UPY levels in subjects with different BC stages and grades. (A) Distribution of  UPY 
levels in subjects with different BC stages. CTRL, n= 170, mean 157.9 ±114.5 SU; CIS, n=4, mean 
400.8 ±114.8 SU;  Ta, n= 53, mean 356.3 ±181.0 SU; T1, n= 20, mean 540.9 ±346.6 SU and T2-3, 
n=15, mean 579.5 ±290.6 SU. UPY levels are significantly different in groups of BC patients with 
different BC stages (Kruskal-Wallis test, p=8.10x10-22).  (B) Distribution of UPY levels in subjects 
with different BC grades. CTRL, n= 170, mean 157.9±114.5 SU; G1, n=29, mean 357.6±217.9 SU; 
G2, n= 29, mean 361.7±122.9 SU and G3, n= 30, mean 584.5±336.4 SU. UPY levels are 
significantly different in groups of BC patients with different BC grades (Kruskal-Wallis test, 
p=6.99x10-22).  The solid lines indicate the mean values; the dotted line indicates the best cut-off 
value. 
Figure 3. UPY levels in BC subjects classified according to WHO 2004 classification of BC. 
Distribution of  UPY levels in subjects classified according to WHO 2004 classification of bladder 
tumors. High grade, n=43, mean 528.06 ± 297.19 SU; Low grade, n=43, mean 354.22 ± 191.16 SU. 
UPY levels are significantly different in groups of BC patients with different BC grade (Kruskal-
Wallis test, p=0.0005). 
Figure 4. UPY levels in relation to classification of recurrence and progression risks. (A) 
Analysis of UPY levels in relation to classification of recurrence risks of BC patients (Kruskal-
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Wallis test, p=0.002). (B) Analysis of UPY levels in relation to classification of progression risk of 
BC patients (Kruskal-Wallis test, p=0.001).  
Figure 5. UPY levels in different subjects age ranges. (A) Distribution of UPY levels in CTRL 
and BC patients age ranges: ≤55 year-old (CTRL, n=53, mean 134.3±123.0 SU; BC, n=11, mean 
326.8±164.9 SU), 56-65 year-old (CTRL, n=72, mean 169.2±114.0 SU; BC, n=25, mean 
437.2±354.5 SU), 66-75 year-old (CTRL, n=28, mean 168.5±108.0 SU; BC, n=37, mean 
431.2±187.1 SU), >75 year-old (CTRL, n=15, mean 168.2±103.4 SU; BC, n=19, mean 501.0±270.6 
SU). UPY levels are significantly increased in BC patients in all age groups (Wilcoxon rank sum 
test). The solid lines indicate the mean values. (B) Distribution of patients with different BC stages: 
data are expressed as percentage in different age groups. (C) Distribution of patients with different 
BC grades: data are expressed as percentage in different age groups. 





